[
  {
    "ts": null,
    "headline": "[Latest] Global Advanced Wound Closure Market Size/Share Worth USD 32.54 Billion by 2035 at a 6.9% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
    "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Advanced Wound Closure Market size & share revenue was valued at approximately USD 18.47 Billion in 2025 and is expected to reach USD 19.68 Billion in 2026 and is expected to reach around USD 32.54 Billion by 2035, at a CAGR of 6.9% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Johnson & Johnson (Ethi",
    "url": "https://finnhub.io/api/news?id=3433ac30132a840866d60fcffaaa9780606709be3b861f6aa31bb1c98ce4c140",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770060600,
      "headline": "[Latest] Global Advanced Wound Closure Market Size/Share Worth USD 32.54 Billion by 2035 at a 6.9% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
      "id": 138335067,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Advanced Wound Closure Market size & share revenue was valued at approximately USD 18.47 Billion in 2025 and is expected to reach USD 19.68 Billion in 2026 and is expected to reach around USD 32.54 Billion by 2035, at a CAGR of 6.9% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Johnson & Johnson (Ethi",
      "url": "https://finnhub.io/api/news?id=3433ac30132a840866d60fcffaaa9780606709be3b861f6aa31bb1c98ce4c140"
    }
  },
  {
    "ts": null,
    "headline": "Merck Reports Earnings Tuesday Morning After Gaining 13% Over the Past Year",
    "summary": "Merck & Co. reports Q4 2025 earnings on Tuesday, Feb. 3, 2026, before market open. Wall Street expects earnings of $2.01 per share on revenue of $16.12 billion, representing 3.1% year-over-year growth. Shares have gained 13% over the past year, outperforming the healthcare sector’s broader returns. Here’s what investors should watch for. The Numbers That ... Merck Reports Earnings Tuesday Morning After Gaining 13% Over the Past Year",
    "url": "https://finnhub.io/api/news?id=fc6b924cd698a23a500b25032cd8f15b3b7caa244fd3482ff96ffe6497c82f0a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770050424,
      "headline": "Merck Reports Earnings Tuesday Morning After Gaining 13% Over the Past Year",
      "id": 138333682,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Merck & Co. reports Q4 2025 earnings on Tuesday, Feb. 3, 2026, before market open. Wall Street expects earnings of $2.01 per share on revenue of $16.12 billion, representing 3.1% year-over-year growth. Shares have gained 13% over the past year, outperforming the healthcare sector’s broader returns. Here’s what investors should watch for. The Numbers That ... Merck Reports Earnings Tuesday Morning After Gaining 13% Over the Past Year",
      "url": "https://finnhub.io/api/news?id=fc6b924cd698a23a500b25032cd8f15b3b7caa244fd3482ff96ffe6497c82f0a"
    }
  },
  {
    "ts": null,
    "headline": "Buy AbbVie Stock Before Q4 Earnings? Here's What to Know",
    "summary": "ABBV heads into Q4 earnings with Skyrizi and Rinvoq driving growth, Humira sales sliding, and shares trading at a discount to the industry.",
    "url": "https://finnhub.io/api/news?id=2b2b6bb954f2599a2c0860c3d68604c5907f7d21719429be437d3834b149ea05",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770046440,
      "headline": "Buy AbbVie Stock Before Q4 Earnings? Here's What to Know",
      "id": 138333691,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "ABBV heads into Q4 earnings with Skyrizi and Rinvoq driving growth, Humira sales sliding, and shares trading at a discount to the industry.",
      "url": "https://finnhub.io/api/news?id=2b2b6bb954f2599a2c0860c3d68604c5907f7d21719429be437d3834b149ea05"
    }
  },
  {
    "ts": null,
    "headline": "What's in Store for These 5 Pharma Bigwigs This Earnings Season?",
    "summary": "As earnings season accelerates, pharma heavyweights LLY, MRK, NVO, BMY and PFE prepare to reveal their Q4 results amid a strong sector start.",
    "url": "https://finnhub.io/api/news?id=80649950b33082b20364be17e694b012330a1b2a8b254d291dc2e8103f26dbe0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770045900,
      "headline": "What's in Store for These 5 Pharma Bigwigs This Earnings Season?",
      "id": 138333684,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "As earnings season accelerates, pharma heavyweights LLY, MRK, NVO, BMY and PFE prepare to reveal their Q4 results amid a strong sector start.",
      "url": "https://finnhub.io/api/news?id=80649950b33082b20364be17e694b012330a1b2a8b254d291dc2e8103f26dbe0"
    }
  },
  {
    "ts": null,
    "headline": "Morgan Stanley Upgrades Johnson & Johnson to Overweight, Increases PT to $262",
    "summary": "Johnson & Johnson (NYSE:JNJ) is one of the 10 Hottest Stocks to Buy in 2026. On January 28, TheFly reported that Morgan Stanley upgraded Johnson & Johnson (NYSE:JNJ) from Equal Weight to Overweight, increasing the price target from $200 to $262. Terence Flynn from Morgan Stanley remains bullish on the company as he expects higher […]",
    "url": "https://finnhub.io/api/news?id=40b878966eaed629a07ef27fdd61a9845a6b28ab05b95418c62ac887d59a854f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770043913,
      "headline": "Morgan Stanley Upgrades Johnson & Johnson to Overweight, Increases PT to $262",
      "id": 138332404,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is one of the 10 Hottest Stocks to Buy in 2026. On January 28, TheFly reported that Morgan Stanley upgraded Johnson & Johnson (NYSE:JNJ) from Equal Weight to Overweight, increasing the price target from $200 to $262. Terence Flynn from Morgan Stanley remains bullish on the company as he expects higher […]",
      "url": "https://finnhub.io/api/news?id=40b878966eaed629a07ef27fdd61a9845a6b28ab05b95418c62ac887d59a854f"
    }
  },
  {
    "ts": null,
    "headline": "Real-world head-to-head analysis shows 51% reduction in risk of death for patients with metastatic castration-sensitive prostate cancer treated with ERLEADA® (apalutamide) versus darolutamide without docetaxel through 24 months",
    "summary": "Johnson & Johnson today announced new real world head-to-head evidence demonstrating that patients with metastatic castration-sensitive prostate cancer (mCSPC) initiating ERLEADA® without docetaxel experienced a statistically significant 51 percent reduction in the risk of death compared to those who initiated on darolutamide without docetaxel through 24-months of follow-up (hazard ratio [HR] 0.49; 95% confidence interval [CI], 0.30–0.83; P=0.007). These findings reflecting patients treated in r",
    "url": "https://finnhub.io/api/news?id=d94ed82e4a2e33ea0d8baa0e34cb87e480069e88daaf5a292e9042f6736cf8dd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770037200,
      "headline": "Real-world head-to-head analysis shows 51% reduction in risk of death for patients with metastatic castration-sensitive prostate cancer treated with ERLEADA® (apalutamide) versus darolutamide without docetaxel through 24 months",
      "id": 138331616,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson today announced new real world head-to-head evidence demonstrating that patients with metastatic castration-sensitive prostate cancer (mCSPC) initiating ERLEADA® without docetaxel experienced a statistically significant 51 percent reduction in the risk of death compared to those who initiated on darolutamide without docetaxel through 24-months of follow-up (hazard ratio [HR] 0.49; 95% confidence interval [CI], 0.30–0.83; P=0.007). These findings reflecting patients treated in r",
      "url": "https://finnhub.io/api/news?id=d94ed82e4a2e33ea0d8baa0e34cb87e480069e88daaf5a292e9042f6736cf8dd"
    }
  }
]